This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Bailey Dove/Victrelis
From Proteopedia
Contents |
Victrelis
Victrelis (boceprevir) is an antiviral Hepatitis C medication approved by the United States Food and Drug Administration in 2011. Victrelis is an inhibitor of the non-structural protein 3 (NS3) serine protease. The medication inhibits viral replication in Hepatitis C virus infected cells. [1]
Disease
Hepatitis C is a blood-borne, single-stranded RNA virus that attacks the liver[2][3]. If left untreated, an acute Hepatitis C infection could lead to chronic hepatitis, liver failure, or liver cancer [4].
Serine Protease NS3
Double-stranded RNA (dsRNA), which is a common intermediate that is found in any given life cycle of many viruses, is a trigger of the immune response[5].
</StructureSection>
References
- ↑ Merck & Co., Inc. (n.d.) Highlights of prescribing information. Retrieved from https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf
- ↑ Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004 Feb;12(2):96-102. PMID:15036326 doi:http://dx.doi.org/10.1016/j.tim.2003.12.005
- ↑ Centers for Disease Control and Prevention. (2015). Viral Hepatitis - Hepatitis C Information. Retrieved from http://www.cdc.gov/hepatitis/hcv/index.htm
- ↑ Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol. 2013 Dec 21;19(47):8963-73. doi: 10.3748/wjg.v19.i47.8963. PMID:24379621 doi:http://dx.doi.org/10.3748/wjg.v19.i47.8963
- ↑ Robalino J, Browdy CL, Prior S, Metz A, Parnell P, Gross P, Warr G. Induction of antiviral immunity by double-stranded RNA in a marine invertebrate. J Virol. 2004 Oct;78(19):10442-8. PMID:15367610 doi:http://dx.doi.org/10.1128/JVI.78.19.10442-10448.2004
